Toward a COVID-19 vaccine strategy for patients with pemphigus on rituximab.
作者信息
Waldman Reid A, Creed Marina, Sharp Kelley, Adalsteinsson Jonas, Imitola Jaime, Durso Timothy, Lu Jun
机构信息
Department of Dermatology, University of Connecticut Health Center, Farmington, Connecticut.
University of Connecticut Health Comprehensive Multiple Sclerosis Center, Department of Neurology, University of Connecticut Health Center, Farmington, Connecticut.
出版信息
J Am Acad Dermatol. 2021 Apr;84(4):e197-e198. doi: 10.1016/j.jaad.2020.10.075. Epub 2020 Oct 29.
Abstract
摘要
相似文献
1
Toward a COVID-19 vaccine strategy for patients with pemphigus on rituximab.针对接受利妥昔单抗治疗的天疱疮患者的新冠疫苗接种策略
J Am Acad Dermatol. 2021 Apr;84(4):e197-e198. doi: 10.1016/j.jaad.2020.10.075. Epub 2020 Oct 29.
2
Rituximab as the treatment of pemphigus vulgaris in the COVID-19 pandemic era: A narrative review.在 COVID-19 大流行期间用利妥昔单抗治疗寻常型天疱疮：一项叙述性综述。
Dermatol Ther. 2021 Jan;34(1):e14405. doi: 10.1111/dth.14405. Epub 2020 Oct 20.
3
Can rituximab be used in the treatment of pemphigus vulgaris during the COVID-19 pandemic?在 COVID-19 大流行期间，可以用利妥昔单抗治疗寻常型天疱疮吗？
Dermatol Ther. 2021 Jan;34(1):e14647. doi: 10.1111/dth.14647. Epub 2020 Dec 15.
4
Estimating the susceptibility to SARS-CoV-2 infection with rituximab use for pemphigus vulgaris.评估使用利妥昔单抗治疗寻常型天疱疮患者对 SARS-CoV-2 感染的易感性。
J Dermatolog Treat. 2022 May;33(3):1606-1607. doi: 10.1080/09546634.2020.1870648. Epub 2021 Jan 12.
5
COVID-19 severity and SARS-Cov-2 vaccine safety in pemphigus patients.天疱疮患者的 COVID-19 严重程度和 SARS-CoV-2 疫苗安全性。
Dermatol Ther. 2022 May;35(5):e15417. doi: 10.1111/dth.15417. Epub 2022 Mar 10.
6
SARS-CoV-2 Vaccination Effectiveness in Rituximab-Treated Patients Affected by Pemphigus Vulgaris.利妥昔单抗治疗的寻常型天疱疮患者中SARS-CoV-2疫苗的有效性
J Invest Dermatol. 2023 Aug;143(8):1601-1604. doi: 10.1016/j.jid.2022.12.023. Epub 2023 Jan 28.
7
Pemphigus vulgaris relapse during the coronavirus disease pandemic.寻常型天疱疮在冠状病毒病大流行期间复发。
Dermatol Ther. 2022 Apr;35(4):e15354. doi: 10.1111/dth.15354. Epub 2022 Feb 12.
8
T Cells Remember SARS-CoV-2 in Rituximab-Treated Pemphigus Vulgaris.利妥昔单抗治疗的寻常型天疱疮患者的T细胞记住了新冠病毒。
J Invest Dermatol. 2023 Aug;143(8):1340-1341. doi: 10.1016/j.jid.2023.02.002. Epub 2023 Mar 21.
9
Rituximab for COVID-19 Vaccine-Associated Pemphigus Vulgaris.
Am J Ther. 2023;30(6):e544-e546. doi: 10.1097/MJT.0000000000001620. Epub 2023 Mar 7.
10
SARS CoV-2 vaccine AND rituximab. Comment on: "SARS CoV-2 vaccine AND rituximab, timing is probably a key for a better vaccine response" by Verhoeven Joint Bone Spine. 2021;88:105258.严重急性呼吸综合征冠状病毒2疫苗与利妥昔单抗。评论：Verhoeven等人在《关节与脊柱》杂志上发表的“严重急性呼吸综合征冠状病毒2疫苗与利妥昔单抗，时机可能是获得更好疫苗反应的关键”。2021年；88:105258 。
Joint Bone Spine. 2022 Jan;89(1):105281. doi: 10.1016/j.jbspin.2021.105281. Epub 2021 Sep 29.
引用本文的文献
1
The challenges of the pandemic and the vaccination against covid-19 in pediatric patients with kidney disease.肾病儿科患者面临的疫情挑战及新冠疫苗接种情况
J Bras Nefrol. 2023 Apr-Jun;45(2):244-251. doi: 10.1590/2175-8239-JBN-2022-0081en.
2
A systematic review on mucocutaneous presentations after COVID-19 vaccination and expert recommendations about vaccination of important immune-mediated dermatologic disorders.一项关于 COVID-19 疫苗接种后黏膜皮肤表现的系统评价和关于重要免疫介导性皮肤病疫苗接种的专家建议。
Dermatol Ther. 2022 Jun;35(6):e15461. doi: 10.1111/dth.15461. Epub 2022 Apr 11.
3
Seroconversion after COVID-19 vaccination for multiple sclerosis patients on high efficacy disease modifying medications.COVID-19 疫苗接种对高效疾病修正治疗药物治疗多发性硬化症患者的血清转化。
Mult Scler Relat Disord. 2022 Apr;60:103719. doi: 10.1016/j.msard.2022.103719. Epub 2022 Mar 3.
4
Impact of COVID-19 on autoimmune blistering diseases.COVID-19 对自身免疫性水疱病的影响。
Clin Dermatol. 2021 May-Jun;39(3):359-368. doi: 10.1016/j.clindermatol.2021.01.007. Epub 2021 Feb 2.
5
Long-Term Safety of Rituximab (Risks of Viral and Opportunistic Infections).利妥昔单抗（病毒和机会性感染的风险）的长期安全性。
Curr Rheumatol Rep. 2021 Jul 16;23(9):74. doi: 10.1007/s11926-021-01037-3.
6
COVID-19 vaccines: What dermatologists should know?新型冠状病毒肺炎（COVID-19）疫苗：皮肤科医生应该了解哪些信息？
Dermatol Ther. 2021 Sep;34(5):e15056. doi: 10.1111/dth.15056. Epub 2021 Jul 13.
7
Case Report: Complete and Fast Recovery From Severe COVID-19 in a Pemphigus Patient Treated With Rituximab.病例报告：用利妥昔单抗治疗的天疱疮患者 COVID-19 后完全快速康复。
Front Immunol. 2021 Apr 16;12:665522. doi: 10.3389/fimmu.2021.665522. eCollection 2021.
8
How to Manage COVID-19 Vaccination in Immune-Mediated Inflammatory Diseases: An Expert Opinion by IMIDs Study Group.如何管理免疫介导的炎症性疾病中的新冠疫苗接种：免疫介导的炎症性疾病研究组的专家意见
Front Immunol. 2021 Apr 15;12:656362. doi: 10.3389/fimmu.2021.656362. eCollection 2021.
本文引用的文献
1
Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study.奥瑞珠单抗对多发性硬化症患者疫苗反应的影响：VELOCE 研究。
Neurology. 2020 Oct 6;95(14):e1999-e2008. doi: 10.1212/WNL.0000000000010380. Epub 2020 Jul 29.
2
Immunizations in immunocompromised patients: a guide for dermatologists.免疫功能低下患者的免疫接种：皮肤科医生指南。
J Dtsch Dermatol Ges. 2020 Jul;18(7):699-723. doi: 10.1111/ddg.14156.
3
COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases.COVID-19 疫苗接种准备与自身免疫性疾病中的抗 CD20 耗竭疗法。
Clin Exp Immunol. 2020 Nov;202(2):149-161. doi: 10.1111/cei.13495. Epub 2020 Aug 1.
4
Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine?抗 CD20 治疗会影响 SARS-CoV-2 疫苗的疗效吗？
Eur J Cancer. 2020 Sep;136:4-6. doi: 10.1016/j.ejca.2020.06.017. Epub 2020 Jun 25.
5
mRNA vaccines - a new era in vaccinology.mRNA 疫苗——疫苗学的新纪元。
Nat Rev Drug Discov. 2018 Apr;17(4):261-279. doi: 10.1038/nrd.2017.243. Epub 2018 Jan 12.
Zotero 插件